Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809608 | 1.00 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| Isopropylamine SCHEMBL28069262 | 0.90 | HTR2A (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12656891 | 0.85 | LMNA (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19722074 | 0.83 | CYP17A1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1277335 | 0.83 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23218 | 0.83 | RAB9A (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18355747 | 0.81 | MAPK1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13785412 | 0.81 | PDE2A (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL178391 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18361620 | 0.81 | TUBB1 (0.53) | KMT2AMAPTMAPK1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103456982-A | Functional electrolyte for improving charge-discharge efficiency of lithium ion battery and application thereof | CHINA NAT OFFSHORE OIL CORP | 2013-12-18 | — | — | CN | claimed |
| CN-101577348-A | Multiplex overcharging protection functional electrolyte for lithium ion battery | UNIV CENTRAL SOUTH (CN) | 2009-11-11 | — | — | CN | claimed |
| CN-101510622-A | Electrolyte for lithium ion secondary battery and battery containing the electrolyte | BYD CO LTD (CN) | 2009-08-19 | — | — | CN | claimed |
| US-20260092058-A1 | Small Molecule Degraders and Fluorescent Probes of PXR | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12516051-B1 | Small molecule degraders and fluorescent probes of PXR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI THERAPEUTICS INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | ATAI THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. | 2024-09-05 | — | — | US | disclosed |
| CN-113728484-B | Electrolyte for lithium secondary battery and lithium secondary battery comprising same | 株式会社LG新能源 | 2024-07-12 | — | — | CN | disclosed |
| US-5929281-A | REACTING A HETROCYCLIC AROMATIC HALIDE WITH AN AMINE COMPOUND IN PRESENCE OF A BASE USING A TRI-TERT-BUTYLPHOSPHINE AND PALLADIUM COMPOUND CATALYST TO FORM HETEROCYCLIC AROMATIC AMINE COMPOUNDS | TOSOH CORPORATION (JP) | 1999-07-27 | — | — | US | disclosed |
| US-5849769-A | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection | MEDIVIR AB (SE) | 1998-12-15 | — | — | US | disclosed |
| EP-0706514-B1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1998-11-18 | — | — | EP | disclosed |
| US-5763119-A | NEGATIVE AND POSITIVE ELECTRODES FOR ELECTROLYTIC CELLS WITH LITHIUM, CARBON AND DOPES | SONY CORPORATION (JP) | 1998-06-09 | — | — | US | disclosed |
| EP-0802173-A1 | Process for producing heterocylic aromatic amine or arylamine | Tosoh Corporation (JP) | 1997-10-22 | — | — | EP | disclosed |
| CN-1138219-A | Non aqueous electroryte secondary cell with shuttle agent | SONY CORP (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0740359-A1 | Non-aqueous electrolyte secondary cell having shuttle agent | SONY CORPORATION (JP) | 1996-10-30 | — | — | EP | disclosed |
| EP-0706514-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995006034-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | CA12 4606/4885CA1 2902/4885CA2 1106/4885 |
| US-12351537-B2 | Dimethoxyphenylalkylamine activators of serotonin receptors | HTR1A, HTR7, HTR4 | CA12 4851/4885CA1 4634/4885CA2 3235/4885 |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | CA12 3683/4885CA1 3217/4885CA2 897/4885 |
| US-20260092058-A1 | Small Molecule Degraders and Fluorescent Probes of PXR | CRBN, VHL, NR1H4 | CA12 1868/4885CA1 715/4885CA2 1061/4885 |
| US-20250282712-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | CA12 4851/4885CA1 4634/4885CA2 3235/4885 |
| US-20240294461-A1 | DIMETHOXYPHENYLALKYLAMINE ACTIVATORS OF SEROTONIN RECEPTORS | HTR1A, HTR7, HTR4 | CA12 4851/4885CA1 4634/4885CA2 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.